Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
The current Vertex Pharmaceuticals(VRTX) stock price is $432.23, with a market capitalization of 108.68B. The stock trades at a price-to-earnings (P/E) ratio of 27.62.
During the trading session on 2026-04-30, Vertex Pharmaceuticals(VRTX) shares reached a daily high of $432.23 and a low of $421.90. At a current price of $432.23, the stock is +2.4% higher than the low and still 0.0% under the high.
Trading activity shows a volume of 1.12M, compared to an average daily volume of 939.81K.
The stock's 52-week range extends from a low of $362.50 to a high of $509.00.
The stock's 52-week range extends from a low of $362.50 to a high of $509.00.
VRTX News
Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $437 from $441 and keeps a Hold rating on the shares. The firm updated its model a...
In recent days, attention on CRISPR Therapeutics has intensified ahead of its March-quarter earnings report, as analysts expect higher revenue and earnings alon...
When you think of the path to wealth, you might immediately think of supercharged technology stocks -- players that may have delivered double or even triple-dig...
Analyst ratings
76%
of 34 ratingsMore VRTX News
Vertex Pharmaceuticals is heading into its March 2026 quarter earnings release, held on May 4, with markets expecting higher revenue and year-over-year earnings...
Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of mark...
Analyst Whitney Ijem from Canaccord Genuity maintained a Hold rating on Vertex Pharmaceuticals and keeping the price target at $441.00. Claim 55% Off TipRanks U...
Vertex Pharmaceuticals received expanded FDA approval for ALYFTREK and TRIKAFTA, extending cystic fibrosis treatment to additional age groups and genetic varian...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.